Editorial: Science and Democracy
By San Francisco Chronicle,
San Francisco Chronicle
| 11. 13. 2005
NOW THAT California taxpayers know that the $3 billion ($6 billion with debt service) that they voted in 2004 to spend on stem-cell research may possibly be an outright grant of money for research rather than an investment, does it make a difference?
Does it matter that Robert Klein, the author and chief promoter of Proposition 71, knew while he was promising the voters a return on their investment that the state might be forbidden to collect royalties from the biomedical research it invests in because of an arcane federal tax law?
What was voters' intent in approving a plan to invest in a promising but financially risky new technology that may someday cure disease and save lives? Were they counting on a financial return, a new industry or promises of cures? And did they assume that they would be affordable to the majority of Californians?
It's important to know the answers to these, and other questions, before the California Institute of Regenerative Medicine, the agency created by the 2004 stem-cell initiative, begins awarding grants of taxpayer funds. Why? Because...
Related Articles
By Rob Stein, NPR | 09.30.2025
Scientists have created human eggs containing genes from adult skin cells, a step that someday could help women who are infertile or gay couples have babies with their own genes but would also raise difficult ethical, social and legal issues...
By Aleks Krotoski, The Guardian | 09.28.2025
Imagine you’re the leader of one of the most powerful nations in the world. You have everything you could want at your disposal: power, influence, money. But, the problem is, your time at the top is fleeting. I’m not...
By Gregory Laub and Hannah Glaser, MedPage Today | 08.07.2025
In this MedPage Today interview, Leigh Turner, PhD, a professor of health policy and bioethics at the University of California Irvine, unpacks the growing influence of stem cell clinics and the blurred line between medicine and marketing. He explains how...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...